2025-2031 Global Mesalamine (Lialda) Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Medical Care > 2025-2031 Global Mesalamine (Lialda) Industry Research & Trends Analysis Report

2025-2031 Global Mesalamine (Lialda) Industry Research & Trends Analysis Report

Publication Date: 2025-09-19
Report Id: 2424559
Industry: Medical Care
Report Page: 135
Chart: 133

PDF Download

Publication Date: 2025-09-19
Report Id: 2424559
Industry: Medical Care
Report Page: 135
Chart: 133

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Mesalamine (Lialda)
1.2 Global Mesalamine (Lialda) Market Size and Forecast
1.3 China Mesalamine (Lialda) Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Mesalamine (Lialda) Share in Global Market, 2020-2031
1.4.2 Mesalamine (Lialda) Market Size: China VS Global, 2020-2031
1.5 Mesalamine (Lialda) Market Dynamics
1.5.1 Mesalamine (Lialda) Market Drivers
1.5.2 Mesalamine (Lialda) Market Restraints
1.5.3 Mesalamine (Lialda) Industry Trends
1.5.4 Mesalamine (Lialda) Industry Policy

2 Competitive Landscape by Company
2.1 Global Mesalamine (Lialda) Revenue by Company, 2020-2025
2.2 Global Mesalamine (Lialda) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Mesalamine (Lialda) Concentration Ratio
2.4 Global Mesalamine (Lialda) Mergers & Acquisitions, Expansion Plans
2.5 Global Mesalamine (Lialda) Manufacturers Product Type
2.6 Global Geographic Distribution of Mesalamine (Lialda) Companies

3 China Competitive Situation by Company
3.1 China Mesalamine (Lialda) Revenue by Company, 2020-2025
3.2 China Mesalamine (Lialda) Mesalamine (Lialda) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Mesalamine (Lialda) Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Mesalamine (Lialda) Industry Chain
4.2 Mesalamine (Lialda) Upstream Analysis
4.3 Mesalamine (Lialda) Midstream Analysis
4.4 Mesalamine (Lialda) Downstream Analysis

5 Sights by Type
5.1 Mesalamine (Lialda) Classification by Type
5.1.1 Tablets
5.1.2 Capsules
5.1.3 Granule
5.1.4 Suppository
5.1.5 Enema
5.1.6 Others
5.2 by Type, Global Mesalamine (Lialda) Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Mesalamine (Lialda) Market Size, 2020-2031

6 Sights by Application
6.1 Mesalamine (Lialda) Segment by Application
6.1.1 Ulcerative Colitis (UC)
6.1.2 Crohn’s Disease (CD)
6.1.3 Others
6.2 by Application, Global Mesalamine (Lialda) Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Mesalamine (Lialda) Market Size, 2020-2031

7 Sights by Region
7.1 By Region, Global Mesalamine (Lialda) Market Size, 2020 VS 2024 VS 2031
7.2 By Region, Global Mesalamine (Lialda) Market Size, 2020-2031
7.3 North America
7.3.1 North America Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Mesalamine (Lialda) Market Size Market Share
7.4 Europe
7.4.1 Europe Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Mesalamine (Lialda) Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Mesalamine (Lialda) Market Size Market Share
7.6 South America
7.6.1 South America Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Mesalamine (Lialda) Market Size Market Share
7.7 Middle East & Africa

8 Sights by Country Level
8.1 By Country, Global Mesalamine (Lialda) Market Size & CAGR，2020 VS 2024 VS 2031
8.2 By Country, Global Mesalamine (Lialda) Market Size, 2020-2031
8.3 United States
8.3.1 United States Mesalamine (Lialda) Market Size, 2020-2031
8.3.2 By Company, United States Mesalamine (Lialda) Revenue Market Share, 2024
8.3.3 by Type, United States Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.3.4 by Application, United States Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Mesalamine (Lialda) Market Size, 2020-2031
8.4.2 By Company, Europe Mesalamine (Lialda) Revenue Market Share, 2024
8.4.3 by Type, Europe Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.4.4 by Application, Europe Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.5 China
8.5.1 China Mesalamine (Lialda) Market Size, 2020-2031
8.5.2 By Company, China Mesalamine (Lialda) Revenue Market Share, 2024
8.5.3 by Type, China Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.5.4 by Application, China Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Mesalamine (Lialda) Market Size, 2020-2031
8.6.2 By Company, Japan Mesalamine (Lialda) Revenue Market Share, 2024
8.6.3 by Type, Japan Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.6.4 by Application, Japan Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Mesalamine (Lialda) Market Size, 2020-2031
8.7.2 By Company, South Korea Mesalamine (Lialda) Revenue Market Share, 2024
8.7.3 by Type, South Korea Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.7.4 by Application, South Korea Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Mesalamine (Lialda) Market Size, 2020-2031
8.8.2 By Company, Southeast Asia Mesalamine (Lialda) Revenue Market Share, 2024
8.8.3 by Type, Southeast Asia Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.8.4 by Application, Southeast Asia Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.9 India
8.9.1 India Mesalamine (Lialda) Market Size, 2020-2031
8.9.2 By Company, India Mesalamine (Lialda) Revenue Market Share, 2024
8.9.3 by Type, India Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.9.4 by Application, India Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Mesalamine (Lialda) Market Size, 2020-2031
8.10.2 By Company, Middle East & Africa Mesalamine (Lialda) Revenue Market Share, 2024
8.10.3 by Type, Middle East & Africa Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031
8.10.4 by Application, Middle East & Africa Mesalamine (Lialda) Revenue Market Share, 2024 VS 2031

9 Company Profile
9.1 Takeda
9.1.1 Takeda Company Information, Head Office, Market Area, and Industry Position
9.1.2 Takeda Company Profile and Main Business
9.1.3 Takeda Mesalamine (Lialda) Models, Specifications, and Application
9.1.4 Takeda Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.1.5 Takeda Recent Developments
9.2 Ferring
9.2.1 Ferring Company Information, Head Office, Market Area, and Industry Position
9.2.2 Ferring Company Profile and Main Business
9.2.3 Ferring Mesalamine (Lialda) Models, Specifications, and Application
9.2.4 Ferring Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.2.5 Ferring Recent Developments
9.3 AbbVie
9.3.1 AbbVie Company Information, Head Office, Market Area, and Industry Position
9.3.2 AbbVie Company Profile and Main Business
9.3.3 AbbVie Mesalamine (Lialda) Models, Specifications, and Application
9.3.4 AbbVie Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.3.5 AbbVie Recent Developments
9.4 Bausch Health
9.4.1 Bausch Health Company Information, Head Office, Market Area, and Industry Position
9.4.2 Bausch Health Company Profile and Main Business
9.4.3 Bausch Health Mesalamine (Lialda) Models, Specifications, and Application
9.4.4 Bausch Health Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.4.5 Bausch Health Recent Developments
9.5 Teva
9.5.1 Teva Company Information, Head Office, Market Area, and Industry Position
9.5.2 Teva Company Profile and Main Business
9.5.3 Teva Mesalamine (Lialda) Models, Specifications, and Application
9.5.4 Teva Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.5.5 Teva Recent Developments
9.6 Mylan
9.6.1 Mylan Company Information, Head Office, Market Area, and Industry Position
9.6.2 Mylan Company Profile and Main Business
9.6.3 Mylan Mesalamine (Lialda) Models, Specifications, and Application
9.6.4 Mylan Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.6.5 Mylan Recent Developments
9.7 Dr. Reddy's Laboratories
9.7.1 Dr. Reddy's Laboratories Company Information, Head Office, Market Area, and Industry Position
9.7.2 Dr. Reddy's Laboratories Company Profile and Main Business
9.7.3 Dr. Reddy's Laboratories Mesalamine (Lialda) Models, Specifications, and Application
9.7.4 Dr. Reddy's Laboratories Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.7.5 Dr. Reddy's Laboratories Recent Developments
9.8 Lupin Limited
9.8.1 Lupin Limited Company Information, Head Office, Market Area, and Industry Position
9.8.2 Lupin Limited Company Profile and Main Business
9.8.3 Lupin Limited Mesalamine (Lialda) Models, Specifications, and Application
9.8.4 Lupin Limited Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.8.5 Lupin Limited Recent Developments
9.9 Sun Pharma
9.9.1 Sun Pharma Company Information, Head Office, Market Area, and Industry Position
9.9.2 Sun Pharma Company Profile and Main Business
9.9.3 Sun Pharma Mesalamine (Lialda) Models, Specifications, and Application
9.9.4 Sun Pharma Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.9.5 Sun Pharma Recent Developments
9.10 Sandoz
9.10.1 Sandoz Company Information, Head Office, Market Area, and Industry Position
9.10.2 Sandoz Company Profile and Main Business
9.10.3 Sandoz Mesalamine (Lialda) Models, Specifications, and Application
9.10.4 Sandoz Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.10.5 Sandoz Recent Developments
9.11 Dr.Falk Pharma
9.11.1 Dr.Falk Pharma Company Information, Head Office, Market Area, and Industry Position
9.11.2 Dr.Falk Pharma Company Profile and Main Business
9.11.3 Dr.Falk Pharma Mesalamine (Lialda) Models, Specifications, and Application
9.11.4 Dr.Falk Pharma Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.11.5 Dr.Falk Pharma Recent Developments
9.12 Zydus Healthcare
9.12.1 Zydus Healthcare Company Information, Head Office, Market Area, and Industry Position
9.12.2 Zydus Healthcare Company Profile and Main Business
9.12.3 Zydus Healthcare Mesalamine (Lialda) Models, Specifications, and Application
9.12.4 Zydus Healthcare Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.12.5 Zydus Healthcare Recent Developments
9.13 Shanghai Pharmaceuticals
9.13.1 Shanghai Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.13.2 Shanghai Pharmaceuticals Company Profile and Main Business
9.13.3 Shanghai Pharmaceuticals Mesalamine (Lialda) Models, Specifications, and Application
9.13.4 Shanghai Pharmaceuticals Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.13.5 Shanghai Pharmaceuticals Recent Developments
9.14 Sunflower Pharmaceutical Group
9.14.1 Sunflower Pharmaceutical Group Company Information, Head Office, Market Area, and Industry Position
9.14.2 Sunflower Pharmaceutical Group Company Profile and Main Business
9.14.3 Sunflower Pharmaceutical Group Mesalamine (Lialda) Models, Specifications, and Application
9.14.4 Sunflower Pharmaceutical Group Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.14.5 Sunflower Pharmaceutical Group Recent Developments
9.15 Sinotherapeutics
9.15.1 Sinotherapeutics Company Information, Head Office, Market Area, and Industry Position
9.15.2 Sinotherapeutics Company Profile and Main Business
9.15.3 Sinotherapeutics Mesalamine (Lialda) Models, Specifications, and Application
9.15.4 Sinotherapeutics Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.15.5 Sinotherapeutics Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Mesalamine (Lialda) should grow from US$ 1942 million in 2024 to US$ 2490 million by 2031, with a CAGR of 3.9% for the period of 2025-2031.

Mesalamine (brand name: Lialda) is an anti-inflammatory drug belonging to the class of aminosalicylates (5-aminosalicylic acid, 5-ASA). It is primarily used to induce and maintain remission in patients with mild to moderate ulcerative colitis. Lialda is an extended-release oral formulation of mesalamine, designed to deliver the drug throughout the colon for localized anti-inflammatory effects.

Mesalamine (Lialda)

According to YH Research, the global market for Mesalamine (Lialda) should grow from US$ 1942 million in 2024 to US$ 2490 million by 2031, with a CAGR of 3.9% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The global prevalence of IBD is rising, particularly in developed regions like North America and Europe, and increasingly in developing nations such as China and India. This increase is largely attributed to changes in lifestyle, dietary habits, and environmental factors, which are contributing to the growing demand for mesalazine.

With ulcerative colitis being the primary indication for mesalazine, the growing number of patients with this condition is directly driving market demand.

Regional demand: North America remains the largest market, supported by high disease prevalence and advanced healthcare systems, while Asia-Pacific is emerging as the fastest-growing region due to rising awareness and healthcare access.

This report aims to provide a comprehensive study of the global market for Mesalamine (Lialda). Report Highlights:
(1) Global Mesalamine (Lialda) market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Mesalamine (Lialda) market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Mesalamine (Lialda) market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Mesalamine (Lialda) segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Mesalamine (Lialda) segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Mesalamine (Lialda) industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Tablets
Capsules
Granule
Suppository
Enema
Others

Market segment by Application, can be divided into
Ulcerative Colitis (UC)
Crohn’s Disease (CD)
Others

Market segment by players, this report covers
Takeda
Ferring
AbbVie
Bausch Health
Teva
Mylan
Dr. Reddy's Laboratories
Lupin Limited
Sun Pharma
Sandoz
Dr.Falk Pharma
Zydus Healthcare
Shanghai Pharmaceuticals
Sunflower Pharmaceutical Group
Sinotherapeutics